Oncternal Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €677.48K -47.3% -€34.07M -9.0% -5,029.2% -21 pp -€27.76M -12.4% -4,097.3% -16 pp
    €1.29M -65.5% -€37.45M +38.6% -2,912.3% -22 pp -€31.68M +38.0% -2,463.4% -18 pp
    €3.72M +27.9% -€27.01M +81.9% -725.4% -2.2 pp -€22.95M +52.0% -616.2% -0.98 pp
    €2.91M +39.2% -€14.85M +8.2% -509.9% +1.5 pp -€15.10M +4.5% -518.4% +1.7 pp
    €2.09M -3.8% -€13.73M -58.6% -656.2% +8.7 pp -€14.45M -57.4% -690.6% +8.7 pp
    €2.18M +50.6% -€33.16M +26.2% -1,523.9% +2.9 pp -€33.96M +67.7% -1,560.7% -1.6 pp
    €1.44M -166.7% -€26.27M +71.7% -1,818.3% -25 pp -€20.25M +13.4% -1,401.3% -22 pp
    -€2.17M -∞% -€15.30M -5.2% 705.9% +7.1 pp -€17.85M +3.3% 823.9% +8.2 pp
    €0.00 +NaN% -€16.14M -52.5% N/A -€17.29M -30.3% N/A
    €0.00 +NaN% -€34.01M -6.4% N/A -€24.82M -34.6% N/A
    €0.00 +NaN% -€36.34M +55.5% N/A -€37.92M +18.9% N/A
    €0.00 -100.0% -€23.37M -18.7% N/A -€31.90M +11.9% N/A
    €12.72M -75.7% -€28.73M -317.7% -225.9% -2.5 pp -€28.51M +8.6% -224.1% -1.7 pp
    €52.31M +311.5% €13.20M -133.1% 25.2% +3.4 pp -€26.26M -33.0% -50.2% +2.6 pp
    €12.71M +8.9% -€39.92M -10.7% -314.0% +0.69 pp -€39.18M +226,885.0% -308.2% -3.1 pp
    €11.68M +89.8% -€44.69M +28.3% -382.8% +1.8 pp -€17.26K -99.9% -0.1% +5.0 pp
    €6.15M -5.0% -€34.83M +13.7% -566.4% -0.93 pp -€30.98M +229.9% -503.8% -3.6 pp
    €6.48M +98.4% -€30.65M -3.6% -473.2% +5.0 pp -€9.39M -67.9% -145.0% +7.5 pp
    €3.26M +102.6% -€31.79M +64.8% -974.1% +2.2 pp -€29.24M +133.7% -895.9% -1.2 pp
    €1.61M +∞% -€19.29M +57.4% -1,197.0% -12 pp -€12.51M +12.5% -776.5% -7.8 pp
    €0.00 +NaN% -€12.25M +19.6% N/A -€11.12M +25.9% N/A
    €0.00 +NaN% -€10.24M +211.3% N/A -€8.84M -∞% N/A
    €0.00 +NaN% -€3.29M +408.3% N/A €0.00 +NaN% N/A
    €0.00 -€647.28K N/A €0.00 N/A

    Notifications